Key Proteo, Inc. — SEC Form D Filing
Key Proteo, Inc. filed an SEC Form D on October 22, 2026, reporting $2.33M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 22, 2026
- Amount reported
- $2.33M
- Round stage
- Seed
- Industry
- Biotechnology
- Website
- https://www.keyproteo.com
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Many treatable rare genetic disorders do not present symptoms until later in childhood or adulthood, leading to prolonged diagnostic delays and potentially irreversible or fatal complications when left undetected.
Solution
Key Proteo develops the Immuno-SRM proteomics platform and screening test kits that pair mass spectrometry with novel panels to quantify extremely low-abundance protein biomarkers, enabling early detection of rare genetic disorders in newborns.
Why now
Rapid growth in targeted gene and enzyme therapies for rare childhood disorders has created an urgent clinical need for high-sensitivity diagnostic assays capable of detecting diseases before symptom onset.
Verdict
Investors backed this round as a piggyback play on the rare disease therapeutics boom, betting that high-cost gene therapies will force clinical labs to adopt ultra-sensitive protein assays before symptoms emerge. This cleared because high-value therapies create external demand for pre-symptomatic identification, not because state newborn screening labs are eager to replace their entrenched mass spectrometry workflows. Durability remains capped by the notoriously slow, price-sensitive state screening procurement infrastructure and the looming long-term risk of whole-genome sequencing bypassing targeted proteomics entirely.
Source: SEC EDGAR Form D filing